A statewide cancer incidence registry for New Jersey.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to R Altman.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
In vitro degradation of fibrinogen results in the appearance of an early fragment, different in its electrophoretic mobility to that of fragments X, Y, D and E. It reacts with antifibrinogen antiserum does not react with anti-D antiserum and it is antigenically related to fragment E. Compared with terminal fragment E, it migrates more slowly towards the anode, it appears earlier and in a greater concentration at the beginning, decreasing and disappearing during degradation. The antigen antibody crossed electrophoresis was used in these experiments, but to distinguish the fragments from already known X, Y or even fibrinogen, the applying of an intermediate gel with anti D was of great value.
Multiple injections of ovomucoid were given to mice with ongoing prolonged IgE antibody production to that antigen. Two inbred strains and antigen doses ranging from 0.05 to 5 mug each injection, given intradermally and subcutaneously, were used. Mice treated in this manner showed a marked diminution of the Ig E antibody booster response as compared to controls. This decrease in booster response was antigen-specific. In addition, a protective effect from anaphylaxis was indicated. The mouse model continues to be a valuable tool for studies of certain IgE-mediated diseases.
An outbreak of febrile respiratory disease at Fort Dix, New Jersey, beginning in January 1976, yielded five isolates of influenza A/New Jersey/76 virus and 42 isolates of strains resembling influenza A/Victoria/75 virus. Despite extraordinary efforts and the study of 305 verified cases of infection with type A influenza virus throughout the region, no additional instances of infections with influenza A/New Jersey virus were detected in humans.
A comparative experimental study has been made to correlate the protamine sulfate test and a modified ethanol gelation test, based on clinical observations of the solubility of a gel formed at 20 degrees C (Godal and Abildgaard procedure) when it was transferred to a bath at 37 degrees C. Two different results were obtained: the gel remained insoluble at 37 degrees C or it became completely soluble, with intermediate degrees of partial solubility. Our studies indicate that this is due to the amount of fibrin monomers formed and the level of fibrinogen: the first are responsible for the insolubility of the gel and the second for its solubility. This furnishes us with useful information for diagnostic purposes. We found the protamine sulfate test more sensitive than the ethanol gelation test, and its sensitivity increased when fibrinogen level decreased. An insoluble gelation test is a sure indication of the presence of fibrin monomers, but a soluble gel calls for the protamine sulfate test to confirm this or the existence of high fibrinogen level.
A high rate of side effects (mostly vestibular) was found among 83 people receiving prophylaxis with minocycline because of contact with a patient who had died of meningitis due to Neisseria meningitidis. Three groups of contacts received different lots of minocycline and different dosage regimens. Seventy-eight percent of these people had symptoms temporally related to ingestion of minocycline. These symptoms, which included dizziness, nausea, vomiting, vertigo, anorexia, and headache, generally commenced soon after initiation of chemoprophylaxis; the total dosage of minocycline was low. The high rate of vestibular side effects of minocycline militates against widespread use of minocycline for prophylaxis of meningococcal infection.
Explore the source record for details and available documents.
Anticoagulation therapy with acenocoumarin or with anticoagulants plus aspirin was given to 65 and 57 patients, respectively, with cardiac valve replacement. The follow-up was 1,462 months (22.5 months per patient) for the first group and 1,411 months (24.7 months per patient) for the second group. The frequency of embolic accidents was significantly lower in the group taking aspirin: Thirteen thromboembolic accidents were detected in patients receiving the anticoagulant and 3 in the group receiving the anticoagulant plus aspirin. These figures represent a 20.3 per cent incidence (one each 9.3 years of treatment) for the anticoagulant group and a 5.2 per cent incidence (one accident each 39.1 years of treatment) for the other group. The statistical significance between groups is p less than 0.005. There was no difference in the hemorrhagic risk between the two groups. We conclude that the use of an anticoagulant plus aspirin is a good and safe therapy for the prevention of thromboembolism in these patients.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.